BR112013015878A2 - "método para determinação da eficácia de uma vacina, kit de reagentes e uso do kit de reagentes" - Google Patents
"método para determinação da eficácia de uma vacina, kit de reagentes e uso do kit de reagentes"Info
- Publication number
- BR112013015878A2 BR112013015878A2 BR112013015878A BR112013015878A BR112013015878A2 BR 112013015878 A2 BR112013015878 A2 BR 112013015878A2 BR 112013015878 A BR112013015878 A BR 112013015878A BR 112013015878 A BR112013015878 A BR 112013015878A BR 112013015878 A2 BR112013015878 A2 BR 112013015878A2
- Authority
- BR
- Brazil
- Prior art keywords
- reagent kit
- vaccine
- efficacy
- determining
- kit
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/35—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Mycobacteriaceae (F)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201061425442P | 2010-12-21 | 2010-12-21 | |
| US61/425,442 | 2010-12-21 | ||
| PCT/EP2011/073609 WO2012085099A1 (en) | 2010-12-21 | 2011-12-21 | Determination of the efficacy of an anti-mycobacterial vaccination |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112013015878A2 true BR112013015878A2 (pt) | 2016-10-04 |
| BR112013015878B1 BR112013015878B1 (pt) | 2020-10-27 |
Family
ID=45446021
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112013015878-6A BR112013015878B1 (pt) | 2010-12-21 | 2011-12-21 | método para determinação da eficácia de uma vacina e kit de reagentes |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US8906389B2 (pt) |
| EP (1) | EP2656070B9 (pt) |
| JP (1) | JP6055780B2 (pt) |
| KR (1) | KR101882040B1 (pt) |
| CN (1) | CN103492877B (pt) |
| AU (1) | AU2011347266B2 (pt) |
| BR (1) | BR112013015878B1 (pt) |
| CA (1) | CA2822715C (pt) |
| CU (1) | CU20130084A7 (pt) |
| CY (1) | CY1117412T1 (pt) |
| DK (1) | DK2656070T3 (pt) |
| EA (1) | EA029833B9 (pt) |
| ES (1) | ES2569035T3 (pt) |
| HK (1) | HK1192322A1 (pt) |
| HR (1) | HRP20160558T1 (pt) |
| HU (1) | HUE027781T2 (pt) |
| MX (1) | MX345961B (pt) |
| PL (1) | PL2656070T3 (pt) |
| PT (1) | PT2656070E (pt) |
| RS (1) | RS54770B1 (pt) |
| SG (1) | SG191331A1 (pt) |
| SI (1) | SI2656070T1 (pt) |
| SM (1) | SMT201600149B (pt) |
| UA (2) | UA112067C2 (pt) |
| WO (1) | WO2012085099A1 (pt) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3543698A1 (en) * | 2018-03-20 | 2019-09-25 | Helmholtz-Zentrum für Infektionsforschung GmbH | Method for determining vaccine efficacy in an individual and means therefore |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0902086A1 (en) * | 1997-08-22 | 1999-03-17 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Tuberculosis vaccine |
| EP1137769B1 (en) * | 1998-11-10 | 2008-09-03 | University Of Rochester | Methods for the generation of dna libraries |
| GB9923309D0 (en) * | 1999-10-01 | 1999-12-08 | Glaxo Group Ltd | Assay |
| JP2001215224A (ja) * | 1999-11-25 | 2001-08-10 | Hitachi Chem Co Ltd | 免疫反応のアッセイ法、免疫学的判定法及びアッセイキット |
| BRPI0409789B8 (pt) | 2003-04-23 | 2021-05-25 | Max Planck Gesellschaft | célula bacteriana, seus processos de preparação e seu uso, composição, e processo para a preparação de uma vacina viva |
| AU2006214473A1 (en) * | 2005-02-14 | 2006-08-24 | Wyeth | Interleukin-17F antibodies and other IL-17F signaling antagonists and uses therefor |
| AU2007261019A1 (en) * | 2006-06-19 | 2007-12-27 | Wyeth | Methods of modulating IL-22 and IL-17 |
| CN101329230B (zh) * | 2008-07-14 | 2010-10-20 | 中国人民解放军第三军医大学 | 改进的免疫荧光细胞染色方法 |
| JP2010051307A (ja) * | 2008-07-28 | 2010-03-11 | Eisai R & D Management Co Ltd | Ｔｈ１７細胞およびＴｒｅｇ細胞の分化誘導を調節する物質のスクリーニング方法 |
| WO2010046039A1 (en) | 2008-10-20 | 2010-04-29 | University Of Zurich | Mycobacterium tuberculosis vaccine |
| JP5931724B2 (ja) * | 2009-06-29 | 2016-06-08 | ジェノセア バイオサイエンシーズ， インコーポレイテッド | ＳｔｒｅｐｔｏｃｏｃｃｕｓＰｎｅｕｍｏｎｉａｅに対するワクチンおよび組成物 |
-
2011
- 2011-12-21 EA EA201300738A patent/EA029833B9/ru not_active IP Right Cessation
- 2011-12-21 CA CA2822715A patent/CA2822715C/en active Active
- 2011-12-21 CN CN201180066448.8A patent/CN103492877B/zh active Active
- 2011-12-21 HU HUE11805020A patent/HUE027781T2/en unknown
- 2011-12-21 PL PL11805020T patent/PL2656070T3/pl unknown
- 2011-12-21 EP EP11805020.2A patent/EP2656070B9/en active Active
- 2011-12-21 ES ES11805020.2T patent/ES2569035T3/es active Active
- 2011-12-21 US US13/996,832 patent/US8906389B2/en active Active
- 2011-12-21 RS RS20160350A patent/RS54770B1/sr unknown
- 2011-12-21 JP JP2013545368A patent/JP6055780B2/ja active Active
- 2011-12-21 BR BR112013015878-6A patent/BR112013015878B1/pt active IP Right Grant
- 2011-12-21 DK DK11805020.2T patent/DK2656070T3/en active
- 2011-12-21 MX MX2013007244A patent/MX345961B/es active IP Right Grant
- 2011-12-21 SG SG2013048756A patent/SG191331A1/en unknown
- 2011-12-21 WO PCT/EP2011/073609 patent/WO2012085099A1/en active Application Filing
- 2011-12-21 SI SI201130785A patent/SI2656070T1/sl unknown
- 2011-12-21 AU AU2011347266A patent/AU2011347266B2/en active Active
- 2011-12-21 UA UAA201308660A patent/UA112067C2/uk unknown
- 2011-12-21 KR KR1020137019197A patent/KR101882040B1/ko active IP Right Grant
- 2011-12-21 PT PT118050202T patent/PT2656070E/pt unknown
- 2011-12-21 UA UAA201308661A patent/UA113282C2/uk unknown
-
2013
- 2013-06-21 CU CU2013000084A patent/CU20130084A7/es unknown
-
2014
- 2014-06-13 HK HK14105616.7A patent/HK1192322A1/xx unknown
-
2016
- 2016-04-25 CY CY20161100335T patent/CY1117412T1/el unknown
- 2016-05-24 HR HRP20160558TT patent/HRP20160558T1/hr unknown
- 2016-05-31 SM SM201600149T patent/SMT201600149B/it unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0822104A2 (pt) | Composições antimicrobianas e métodos para o uso das mesmas | |
| BRPI0911297A2 (pt) | composição e métodos para preparo e uso das mesmas | |
| BRPI0811635A2 (pt) | Compostos de arilazol-2-il cianoetilamino, métodos para fazê-los e métodos para o uso dos mesmos | |
| BR112012022879A2 (pt) | composto, composição farmacêutica, uso do composto e método de tratamento | |
| BRPI0820556A2 (pt) | Bactéria e métodos para uso das mesmas | |
| BRPI0811979A2 (pt) | Formulação para vacinas de meningite | |
| BR112013010988A2 (pt) | composição fluída e uso | |
| BRPI0909770A2 (pt) | Vacina, e, kit | |
| BRPI0922885A2 (pt) | anticorpos humanos de alta afinidade para a pcsk9. | |
| BRPI0915928A2 (pt) | composições e métodos de uso para anticorpos terapêuticos | |
| BRPI0919014A2 (pt) | composição fixadora de cabelo, e, uso de uma composição | |
| BR112012031232A2 (pt) | método, dispositivo e uso | |
| BR112012031226A2 (pt) | composto, uso do composto, composição farmacêutica, e uso de composição farmacêutica | |
| BRPI0922174A2 (pt) | preparação farmacêutica, uso de uma preparação, e, método para preparar uma preparação farmacêutica | |
| BR112013006016A2 (pt) | compostos de azabenzotiazol, composições e métodos de uso | |
| BR112015000534A2 (pt) | método para a preparação de 2,4-dihidroxibutirato, microrganismo, organismo e uso | |
| BR112013010272A2 (pt) | métodos analíticos e arranjos para uso nos mesmos | |
| BR112012016229A2 (pt) | método para melhorar a sobrevida livre de progressão, método in vitro, kit, uso de um oligonucleotídeo ou polipetídeo e uso de bevacizumab | |
| BRPI0808813A2 (pt) | método para a preparação de compostos de borracha, e, uso de compostos | |
| BR112013001423A2 (pt) | método, método in vitro, uso e kit útil para realizar o método | |
| BR112013003530A2 (pt) | ''produto farmacêutico, kit, uso e preparações'' | |
| BRPI0919794A2 (pt) | dispositivo para uso intracorpóreo, e, composto | |
| BR112014008089A2 (pt) | método para diagnosticar o mal de alzheimer, uso do método, e, kit para a realização do método | |
| BR112014029642A2 (pt) | composto, combinação de um composto, composição farmacêutica, uso de um composto, dispositivo e kit | |
| BRPI0912687A2 (pt) | uso de bactéria probiótica para o tratamento de hiperhomocisteinaemia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] |
Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI. |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/12/2011, OBSERVADAS AS CONDICOES LEGAIS. |